Form 4: Celldex Therapeutics CEO Anthony Marucci Buys $308,000 in Company Stock
SEC Form 4 Filing
Celldex Therapeutics CEO Anthony Marucci recently purchased 11,500 shares of the company's common stock at a price of $26.82 per share.
Summary
- On November 11, 2024, Anthony S. Marucci, the President and CEO of Celldex Therapeutics, Inc., purchased 11,500 shares of the company's common stock.
- The purchase price was $26.82 per share.
- Following the transaction, Marucci directly owns 40,284 shares of Celldex Therapeutics.
- This includes 1,092 shares acquired through the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive signal, but it's a routine transaction and doesn't provide significant new information about the company's fundamentals.
Positives
- The CEO's purchase of a significant number of shares could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 11/11/2024 | Date of stock purchase transaction |
| 11/12/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.